Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
Century Therapeutics (NASDAQ: IPSC), a biotech company focused on developing iPSC-derived cell therapies for immuno-oncology and autoimmune disease, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. CEO Brent Pfeiffenberger and CSO Chad Cowan will engage in a fireside chat on November 12, 2024, at 9:30am ET. The presentation will be accessible via live webcast on the company's investor relations website, with replay available for 90 days post-event.
Century Therapeutics (NASDAQ: IPSC), una azienda biotech focalizzata nello sviluppo di terapie cellulari derivate da iPSC per l'immuno-oncologia e le malattie autoimmuni, ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. Il CEO Brent Pfeiffenberger e il CSO Chad Cowan parteciperanno a una chiacchierata informale il 12 novembre 2024, alle 9:30 ET. La presentazione sarà accessibile tramite webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, con la possibilità di rivederla per 90 giorni dopo l'evento.
Century Therapeutics (NASDAQ: IPSC), una empresa biotecnológica enfocada en el desarrollo de terapias celulares derivadas de iPSC para la inmuno-oncología y enfermedades autoinmunitarias, ha anunciado su participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim. El CEO Brent Pfeiffenberger y el CSO Chad Cowan participarán en una charla informal el 12 de noviembre de 2024, a las 9:30 am ET. La presentación estará disponible a través de una transmisión en vivo en el sitio web de relaciones con inversionistas de la empresa, con la opción de volver a verla durante 90 días después del evento.
센추리 테라퓨틱스 (NASDAQ: IPSC)는 면역 종양학 및 자가면역 질환을 위한 iPSC 유래 세포 치료제 개발에 집중하는 생명 공학 회사로, 구겐하임 최초의 의료 혁신 회의에 참여한다고 발표했습니다. CEO 브렌트 페이펜버거와 CSO 채드 카우안은 2024년 11월 12일 오전 9:30 ET에 대화에 참여할 예정입니다. 프레젠테이션은 회사의 투자자 관계 웹사이트에서 라이브 웹캐스트를 통해 제공되며, 행사 종료 후 90일 동안 다시 볼 수 있습니다.
Century Therapeutics (NASDAQ: IPSC), une entreprise biopharmaceutique axée sur le développement de thérapies cellulaires dérivées d'iPSC pour l'immuno-oncologie et les maladies auto-immunes, a annoncé sa participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim. Le PDG Brent Pfeiffenberger et le CSO Chad Cowan participeront à une discussion informelle le 12 novembre 2024 à 9h30 ET. La présentation sera accessible via un webinaire en direct sur le site des relations investisseurs de l'entreprise, avec une rediffusion disponible pendant 90 jours après l'événement.
Century Therapeutics (NASDAQ: IPSC), ein Biotechnologieunternehmen, das sich auf die Entwicklung von iPSC-abgeleiteten Zelltherapien für die Immunonkologie und Autoimmunerkrankungen konzentriert, hat seine Teilnahme an Guggenheims erster Gesundheitsinnovationskonferenz angekündigt. CEO Brent Pfeiffenberger und CSO Chad Cowan werden am 12. November 2024 um 9:30 Uhr ET an einem Gespräch teilnehmen. Die Präsentation wird über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:30am ET.
A live webcast of the event can be accessed on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit www.centurytx.com.
For More Information:
Investor Relations & Media Contacts
Century Therapeutics
Katja Buhrer
SVP, Head of Corporate Affairs and Strategy
katja.buhrer@centurytx.com
917-969-3438
Argot Partners
Julie Seidel/Noor Pahlavi
century@argotpartners.com
212-600-1902
FAQ
When is Century Therapeutics (IPSC) presenting at Guggenheim's Healthcare Innovation Conference 2024?
Who will represent Century Therapeutics (IPSC) at the Guggenheim Healthcare Conference?
How long will the Century Therapeutics (IPSC) webcast replay be available?
Where can I watch Century Therapeutics' (IPSC) Guggenheim Conference presentation?
